Marcumar (Phenprocoumon)

Marcumar is a vitamin K antagonist used in the management of clotting disorders and related conditions.

• Prevention of thromboembolic events: reduces the risk of clot formation in at‑risk patients.
• Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension.
• Prevention of stroke in atrial fibrillation: lowers the incidence of embolic stroke in patients with irregular heart rhythm.

• Phenprocoumon inhibits the enzyme vitamin K epoxide reductase, which is essential for recycling vitamin K to its active form. By blocking this step, the synthesis of vitamin K‑dependent clotting factors II, VII, IX and X in the liver is reduced, leading to a prolonged coagulation time and decreased tendency for thrombus formation.

Phenprocoumon may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Minor bleeding or bruising: easy bruising, gum bleeding, or nosebleeds.
• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
• Headache or dizziness: transient sensations of light‑headedness.

Serious or Rare Side Effects

• Intracranial hemorrhage: bleeding within the brain, a medical emergency.
• Severe gastrointestinal bleeding: blood in stool or vomiting blood.
• Skin necrosis: painful skin lesions, often at sites of fat tissue.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Liver enzyme elevation: abnormal liver function tests indicating hepatic stress.
• Thrombocytopenia: low platelet count leading to increased bleeding risk.

Before initiating therapy with Marcumar, several safety considerations should be addressed.

• INR monitoring: regular blood tests are required to keep the International Normalized Ratio within the therapeutic range.
• Surgical procedures: discontinue or adjust dose before elective surgery to minimise bleeding.
• Liver disease: use with caution in patients with hepatic impairment, as metabolism may be altered.
• Renal impairment: dose adjustments may be necessary for reduced kidney function.
• Concomitant medications: inform healthcare providers of all drugs, especially antiplatelet agents or NSAIDs.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Phenprocoumon interacts with many medicines, requiring careful management.

Major Interactions (Avoid)

• Other vitamin K antagonists (e.g., warfarin): additive anticoagulant effect.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase plasma levels, raising bleeding risk.
• NSAIDs (e.g., ibuprofen, naproxen): enhance gastrointestinal bleeding.
• Antiplatelet agents (e.g., clopidogrel, aspirin): combined effect on hemostasis.
• Vitamin K supplements or high‑vitamin K foods: reduce anticoagulant efficacy.

Moderate Interactions (Monitor Closely)

• Certain antibiotics (e.g., macrolides, quinolones): may alter INR.
• SSRIs and SNRIs: increase bleeding tendency.
• Diuretics (e.g., furosemide): affect plasma protein binding.
• Thyroid hormones: may potentiate anticoagulant effect.
• Herbal products (e.g., ginkgo, garlic): possible enhancement of bleeding.